CGONHIGH SIGNALFINANCIAL10-K

CGON's cash position collapsed 87% to $32.5M while losses nearly doubled, creating a severe liquidity crisis for this single-product biotech company.

The dramatic cash burn acceleration combined with the 68% increase in operating cash outflow suggests CGON is rapidly approaching a funding cliff that could force dilutive equity raises or compromise clinical development timelines. With only one product candidate (cretostimogene) and mounting R&D expenses, the company faces existential risk if it cannot secure additional financing soon.

Comparing 2026-02-27 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

CGON's financial position deteriorated dramatically across all key metrics, with cash plummeting from $257M to $32M while net losses expanded from $88M to $161M driven by 42% higher R&D spending. Operating cash flow worsened significantly to -$132M, and total liabilities surged 82% to $39M, indicating accelerating cash burn and mounting obligations. This represents a classic biotech liquidity crisis where a single-asset company is burning through capital at an unsustainable rate while approaching critical funding thresholds.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-87.4%
$257.1M→$32.5M

Cash declined 87.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-82.9%
-$88.0M→-$161.0M

Net income declined 82.9% — review whether driven by operations, interest costs, or non-recurring items.

Total Liabilities
Balance Sheet
+82%
$21.4M→$39.0M

Liabilities grew 82% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Cash Flow
Cash Flow
-68.1%
-$78.7M→-$132.3M

Operating cash flow fell 68.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-66.4%
-$114.7M→-$190.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+44.3%
$21.4M→$30.8M

Current liabilities surged 44.3% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-42.7%
$234K→$134K

Capex reduced 42.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+42.1%
$82.1M→$116.6M

R&D investment increased 42.1% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-28
ADDED
As of February 25, 2026, t he registrant had 84,435,200 shares of common stock ($0.0001 par value) outstanding.
1 RISK FACTORS SUMMARY The risks described in the section titled Risk Factors in Part I of this Annual Report could impact our ability to realize the full benefits of our strengths or execute all or part of our strategy.
Some of the more significant risks described in Risk Factors include the following: Risks Related to the Development and Regulatory Approval of Our Product Candidates We currently depend entirely on the success of cretostimogene, which is our only product candidate.
If we are unable to advance cretostimogene in clinical development, obtain regulatory approval and ultimately commercialize cretostimogene, or experience significant delays in doing so, our business will be materially harmed.
Cretostimogene is based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval, if at all.
+7 more — sign up free →
REMOVED
As of March 21, 2025, the registrant had 76,216,855 shares of common stock ($0.0001 par value) outstanding.
Overview We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Our goal is to develop cretostimogene grenadenorepvec (cretostimogene), our product candidate, as an alternative to Bacillus Calmette-Gu rin (BCG) in treating a broad range of bladder cancer indications.
Cretostimogene is in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to BCG therapy, the current standard-of-care for high-risk NMIBC.
Given the limitations of currently approved therapies, the next course of treatment for these BCG-unresponsive patients is radical cystectomy, or the complete removal of the bladder, which is associated with significant social, functional and emotional burden.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →